A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Summary

This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).

Timeline

Start

2025-03-14

Primary completion

2026-12

Completion

2027-05

Drugs

Indications